Fatty Liver Disease Has a Gut Microbiome Fingerprint, 1,401-Person Study Finds

Fatty liver disease has quietly become one of the most common chronic conditions on the planet, yet the biological mechanisms driving it remain only partially understood. A new study published in June 2026 adds an important piece to that puzzle, identifying specific gut microbiome signatures in people with metabolic dysfunction-associated steatotic liver disease (MASLD), the updated clinical name for what was formerly called non-alcoholic fatty liver disease. The findings, drawn from a cohort of 1,401 participants in China, suggest that shifts in gut bacteria may be both a marker and a contributor to the disease's progression.

MASLD Gut Microbiota Shows Reduced Diversity and Network Fragility

The research team, led by Ma Y and colleagues, compared gut microbiota from 392 MASLD patients against 1,009 healthy controls drawn from the Healthy Zhejiang One Million People Cohort (HOPE), a large-scale precision health initiative. Using shotgun metagenomic sequencing, which reads the genetic material of all microorganisms in a sample rather than targeting specific marker genes, the team analyzed both the composition and functional potential of each participant's gut microbiome.

The results were striking across multiple dimensions. MASLD patients showed significant alterations in both alpha diversity, the variety of species within an individual, and beta diversity, the degree to which microbial communities differ between individuals. Beyond simple counts, the gut microbial network in MASLD patients also showed reduced connectivity and robustness, meaning the ecological relationships between bacterial species were weaker and less stable. A fragile microbial network is generally associated with a gut ecosystem more vulnerable to further disruption.

Twelve Microbial Strains Separate MASLD Patients From Healthy Controls

Drilling into the specific organisms involved, the study identified changes in 12 microbial strains. Two strains, t_SGB4749 and t_SGB4753, were enriched in MASLD patients. Ten others were depleted. The depletion pattern is consistent with a broader picture seen in other gut-liver research: bacteria associated with short-chain fatty acid (SCFA) production and anti-inflammatory activity tend to diminish, while potentially pathogenic or pro-inflammatory organisms gain ground.

Beyond which strains were present or absent, the team found shifts in what those microbes appeared capable of doing. MASLD patients' gut microbiomes showed elevated genomic potential for lipopolysaccharide (LPS) biosynthesis. LPS is a molecule found in the outer membrane of certain bacteria that, when it leaks from the gut into circulation, can trigger TLR4 signaling in the liver, driving inflammation. The microbiomes also showed increased glycolysis potential alongside decreased pyruvate metabolism, patterns that suggest the microbial community has shifted toward a metabolic profile that could amplify the host's own metabolic dysfunction.

How a Million-Person Cohort Made This Analysis Possible

The scale and design of the HOPE cohort gave this study unusual statistical power. Enrollment of the 1,401 participants took place between January 2022 and June 2023, with multi-dimensional data collected on genomics, lifestyle, physical examinations, and environmental factors. Recruiting nearly 400 MASLD patients alongside more than 1,000 matched healthy controls within a single cohort minimizes many of the confounding variables that plague smaller, more heterogeneous microbiome studies.

The use of shotgun metagenomic sequencing, rather than 16S rDNA amplicon sequencing, is also methodologically significant. It captures functional gene content and allows strain-level resolution, which is why the researchers could identify not just which species were altered but what metabolic programs those species were running. Multi-omics approaches in MASLD research have increasingly shown that knowing what the microbiome is doing matters as much as knowing who is in it.

Causality Remains Open, and Microbiome Signals Are Not Disease-Specific

The study's cross-sectional design is the most important caveat to hold in mind. Because participants were measured at a single point in time, the data can show that microbial changes accompany MASLD but cannot establish whether those changes preceded the disease, developed alongside it, or resulted from it. The authors acknowledge that mechanistic follow-up studies are needed to resolve the causal direction.

There is also a broader challenge in the field. As noted in nutritional intervention research, MASLD microbiome research faces a specificity problem: many of the gut perturbations observed in MASLD patients are also seen in obesity, type 2 diabetes, and other metabolic conditions, and are heavily shaped by diet and medication use. That overlap makes it difficult to define a microbiome signature that is truly liver-specific rather than a reflection of metabolic ill-health more generally. The authors note that methodological heterogeneity and the interindividual nature of the microbiome may warrant personalized interventions and clearer dysbiosis definitions going forward.

Microbiome-Based Therapies for MASLD Are an Active Research Target

Despite these caveats, the findings carry real clinical weight given how large MASLD has become as a global health problem. MASLD affects an estimated 25 to 30 percent of adults worldwide, with prevalence reaching roughly 70 percent among people with type 2 diabetes. Projections suggest that global MASLD rates could exceed 55 percent of adults by 2040, and the disease has already become the leading indication for liver transplant in certain patient populations in the United States.

Against that backdrop, identifying specific microbial strains and functional pathway shifts gives researchers concrete targets. Ongoing work on gut microbiota interventions aims to determine whether modulating bacterial communities can reduce hepatic inflammation and slow the progression from steatosis toward more serious fibrosis or liver cancer. Approaches under investigation include prebiotics, probiotics, fecal microbiota transplantation, and dietary interventions designed to restore SCFA-producing bacteria. The two enriched strains identified here, t_SGB4749 and t_SGB4753, represent specific hypotheses that future intervention studies could test directly: if these strains are contributing to LPS-driven liver inflammation, targeted suppression of them could be one therapeutic lever.

The study does not deliver a treatment. What it does deliver is a more detailed map of the microbial terrain in MASLD, built from one of the largest cohorts yet assembled for this question. That map will need longitudinal studies and mechanistic experiments to become clinically actionable, but it meaningfully narrows the field of candidates worth pursuing.

Evidence rating

EMERGING — 86/100

Caveats:

• Cross-sectional design shows association only — it cannot establish whether gut microbiome changes cause MASLD or result from it.
• Single-cohort study from one site in China; findings may not generalize to other populations.
• Funding source was not disclosed by the authors.
• Mechanistic links between the identified strains and liver disease require validation in longitudinal or interventional studies.

Cross-sectional cohort study (n=1,401) using shotgun metagenomic sequencing to compare gut microbiome composition between MASLD patients and healthy controls. The study identifies associations between specific microbial strains and metabolic pathway shifts, but the design cannot establish causation. Findings are consistent with prior MASLD microbiome literature but have not yet been independently replicated in an external cohort.

References

1. Yuyang Ma, Min Yang, Andi Xu, et al. (2026). Characterization of gut microbiome signatures in metabolic dysfunction associated steatotic liver disease. npj Biofilms and Microbiomes. https://doi.org/10.1038/s41522-026-01059-8
2. Muyesaier Maimaitiyiming, Sulitanguli Maihemuti, Tangnuer Aierken, et al. (2025). Multi-omics analysis reveals gut microbial and metabolic signatures in metabolic dysfunction-associated steatotic liver disease. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2025.1666110
3. Carlo Acierno, Alfredo Caturano, Fannia Barletta, et al. (2026). Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation. Nutrients. https://doi.org/10.3390/nu18111765
4. Dalia M. Miller, Kiana F. McCauley, Kimberly J. Dunham‐Snary (2025). Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): Mechanisms, Clinical Implications and Therapeutic Advances. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70132
5. Zobair M. Younossi, Markos Kalligeros, Linda Henry (2025). Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0431
6. Yu Geng, Lanqing Liu, Yongping Sun, Lijuan Guo, Yuanjing Wu, Zhen Jia (2025). Metabolic dysregulation in MASLD-associated HCC: diagnostic biomarkers and therapeutic opportunities. Frontiers in Medicine. https://doi.org/10.3389/fmed.2025.1705723